Biomarker development for oncology should integrate scientific, medical, and operational considerations. Recent advancements in discovery research for biomarkers further necessitate their integration and present implications for the operations of clinical trials. Read this white paper for an overview of oncology biomarker development, to discover the considerations for determining biomarkers in an early phase trial, for insight on collecting biomarker samples, and to understand the implications of biomarker selection on commercialization.
Authors:
Craig Dorer-Abadia
Senior Director, Project Management, Oncology
Michael Murphy, MD, PhD
Chief Medical and Scientific Officer
